Artelo Biosciences, Inc.
ARTL
$5.98
-$0.21-3.39%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 7.25M | 6.90M | 5.98M | 5.42M | 4.48M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 11.07M | 11.71M | 11.40M | 12.43M | 10.54M |
| Operating Income | -11.07M | -11.71M | -11.40M | -12.43M | -10.54M |
| Income Before Tax | -12.67M | -13.47M | -12.88M | -12.49M | -10.50M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -12.67 | -13.47 | -12.88 | -12.49 | -10.50 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -12.67M | -13.47M | -12.88M | -12.49M | -10.50M |
| EBIT | -11.07M | -11.71M | -11.40M | -12.43M | -10.54M |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -206.75 | -350.47 | -427.40 | -560.67 | -510.44 |
| Normalized Basic EPS | -119.82 | -209.56 | -257.64 | -351.48 | -322.06 |
| EPS Diluted | -206.75 | -350.47 | -427.40 | -560.67 | -510.44 |
| Normalized Diluted EPS | -119.82 | -209.56 | -257.64 | -351.48 | -322.06 |
| Average Basic Shares Outstanding | 487.40K | 207.30K | 146.20K | 91.30K | 82.10K |
| Average Diluted Shares Outstanding | 487.40K | 207.30K | 146.20K | 91.30K | 82.10K |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |